Stoke Therapeutics, Inc. (STOK): Total Assets
$418.43M
As of 2025-12-31
$393.97M
As of 2026-06-30
+17.8%
3-year compound annual growth
+7.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $418.43M | +54.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $271.56M | +18.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $228.34M | -10.8% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $256.07M | +7.2% | 2024-03-25, Balance as of period end |
| 2021-12-31 | $238.87M | -19.8% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $297.93M | +30.2% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $228.75M | +112.7% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $107.54M | n/a | 2020-03-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $770.58M | -23.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $62.11M | -13.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $764.99M | +8.7% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $259.15M | -31.5% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $529.71M | -26.9% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗